(MENAFN- MSCOMMS) Clinical trial shows ClearPlasma from Plas-Free reduces bleeding and hospitalization time for patients with upper gastrointestinal bleeding
NAZARETH, Israel, 13 April 2021 – Plas-Free, an NGT3 VC portfolio company, has successfully completed the open label phase of its recent clinical trial by enrolling 5 patients with upper gastrointestinal bleeding in Israel.
In parallel, the Company has recruited 5 additional patients in its multi-center (Italy and Czech Republic), double blind, randomized clinical study on upper gastrointestinal bleeding. It's planned that the Israeli sites will join the multi-center study following the approval of the safety of the open label phase by the Israeli Ministry of Health.
''The results of this phase demonstrate the safety of the company's technology and also the first signs of efficacy in reducing bleeding and hospitalization time,” said Plas-Free CEO Dr. Zeev Dvashi.
The Plas-Free team worked together to develop ClearPlasma™, a disposable filtration system that improves the treatment of patients with massive bleeding. By extracting plasminogen, a naturally-occurring protein responsible for dissolving blood clots, ClearPlasma transforms blood plasma to enhance coagulation and favor haemostasis.
Plas-Free is part of Nazareth-based NGT3, a VC firm investing in life science startups led by Arab and Jewish entrepreneurs with a strong belief that the most effective platform for strengthening Jewish-Arab relations is an economic one, allowing for collaboration and the opportunity to build meaningful relationships.
Products developed by NGT3 portfolio companies are already saving lives by making cancer surgery safer for women, helping patients suffering from chronic heart or kidney failure, preventing hemorrhage, and accelerating healing after neurosurgery.
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.